KR102172916B1 - Compositions containing silk peptide and natural extracts for improving cognitive function - Google Patents

Abstract

The present invention relates to a composition for improving cognitive function comprising a silk peptide and a natural extract. The composition for improving cognition according to an embodiment of the present invention can provide a composition having an effect on improving cognitive function by utilizing an extract derived from a natural product, and for improving cognitive function including the silk peptide and natural extract of the present invention The composition is provided as a pharmaceutical composition, and compared to the case of using only the conventional silk peptide, a composition with improved cognitive function can be provided. In addition, in the case of the functional food composition of the present invention, it can be provided as a functional food composition having a high preference while improving cognitive function.

Description

A composition for improving cognitive function containing silk peptides and natural extracts {COMPOSITIONS CONTAINING SILK PEPTIDE AND NATURAL EXTRACTS FOR IMPROVING COGNITIVE FUNCTION}

The present invention relates to a composition for improving cognitive function comprising a silk peptide and a natural extract. More specifically, it relates to a composition for improving cognitive function comprising as an active ingredient a silk peptide produced by decomposition of silk protein and a natural extract obtained from a natural product.

Stroke is a cerebrovascular disease that causes dysfunction of local brain tissue as a result of rupture or blockage of cerebrovascular blood vessels. It is often referred to as stroke, and is leading the cause of death in Korea. Moreover, the incidence rate is gradually increasing due to the prolongation of life expectancy due to industrialization and the development of medicine. Stroke can occur in any part of the brain and thus impair almost every function of the body. Medically, stroke can be classified into'ischemic stroke', which occurs because blood circulation to a specific area is not possible due to large blockage of blood vessels in the brain, and'hemorrhagic stroke' caused by cerebral hemorrhage. Among them, it is closely related to high blood pressure and atherosclerosis, which are known causes of adult diseases. The incidence of ischemic stroke is higher.

Ischemic stroke occurs when a blood vessel is blocked anywhere, from the carotid artery in the neck and the vertebral floor artery to the slender artery in the brain. This causes the brain tissue dominated by the blood vessels to die, namely,'infarction'. Will occur. Once a cerebral infarction has occurred, its function cannot be restored, and thus the central nervous system disorder caused by a cerebral infarction is not recovered and remains permanently. Therefore, the most important thing in the treatment of stroke is the prevention of cerebral ischemia itself, along with prevention methods such as hypertension, diabetes, and hyperlipidemia, which are known as risk factors for stroke. In addition, the focus is on reducing cerebral edema when a cerebral infarction occurs due to a stroke onset, and appropriate circulation in ischemic areas to reduce secondary brain damage.

Substances currently used for the protection of nerve cells include ganglioside, nimodipine, and clomethiazole, a GABA agonist, and magnesium sulfate and glycine antagonists are 2 Phase clinical studies are underway, and piracetam is currently undergoing large-scale clinical studies. However, the neuroprotective agents currently being tried are agents that act at different stages of the ischemia process. Although it is necessary to develop a combination therapy that simultaneously acts on these various processes, the problem of side effects and drug interactions must be solved. Is hugging.

In addition, since the symptoms of ischemic stroke come suddenly without a specific prognosis, rather than expecting treatment through drugs administered at the time of the onset of cerebral ischemia, the intake of functional foods to prevent ischemia and suppress apoptosis of nerve cells after ischemia is more effective. It is being judged.

Parkinson's disease (PD), a neurodegenerative disease, is a neurodegenerative disease that causes motor and cognitive impairments and was first reported by James Parkinson in 1817. The incidence rate of this disease is about 100-150 per 100,000 population in the United States, and about 750,000-1 million patients are reported, and about 60,000 are newly diagnosed every year. The prevalence is expected to continue to increase. Histopathology is characterized by the loss of dopamine neurons located in the substantia nigra, and characteristic progression due to a decrease in dopamine in the caudate nucleus and putamen, which are the projection sites of the nerve fibers ( tremor), motor delay (bradykinesia), stiffness (rigidity), and disturbance of posture (disturbance of posture).

The main therapeutic drugs used for Parkinson's disease are drugs that supplement the function of dopamine deficient in the brain, or other drugs for the purpose of preventing or delaying the destruction of nerve cells, or for controlling ancillary symptoms such as depression. Etc. Representative drugs include levodopa (L-dopa), a dopamine precursor, and Madopa, a dopamine receptor agonist, bromidine, lisuride, and an anti-acetylcholinergic drug, Altan. Various neuropharmacological compensatory treatments such as (artane) and cogentin have been developed. Of these, levodopa, a precursor of dopamine, is most effectively used to improve the symptoms of Parkinson's disease by supplementing the insufficient concentration of dopamine in the brain.However, if administered for a long period of 3-5 years or longer, the drug effect time becomes shorter (wearing-off) or a drug Side effects such as an on-off phenomenon, diskinesia, and other side effects occur (Freed et. al., N. Engl. J. Med. 327:1549-) 55(1992)).

Other surgical treatments for Parkinson's disease include thalamustomy, pallidotomy, deep brain stimulation, and neuronal cell transplantation. However, the duration of the treatment effect varies greatly from patient to patient, and rarely, accompanied by side effects such as hypophonia, dysarthria, and memory attenuation following surgery (Ondo et. al., Neurology 50:266-270 (1998); Shannon et.al., Neurology 50:434-438 (1998)).

Recent treatment stances for Alzheimer's disease have centered on the possibility that Alzheimer's disease is derived from cholinergic signaling and transmission with impaired function in the cerebral cortex and hippocampus (Bartus et al. , Science.217(4558): 408-14(1982)); And Coyle et al., Science. 219(4589):1184-90(1983)). Since these areas of the brain are linked to memory and intelligence, functional deficiencies in these parts of the brain cause significant damage to memory and judgment and loss of intellectual abilities. Although the exact process by which neuronal signaling is impaired is debated, sensory plaques and neurofibrillary tangles (NFTs) are considered to be the main causes of nerve damage. Sensory plaque caused by the accumulation of amyloid beta (Aβ) is the most important feature of this disease, and Alzheimer's disease can be confirmed by post-mortem autopsy (Khachaturian, Arch. Neurol. 42(11):1097-105(1985)).

In the case of Alzheimer's disease, drugs and treatments that increase the amount of acetylcholine to inhibit damage to cholinergic signaling, allow acetylcholine to exist for a long period of time, or to make acetylcholine more effective in neuronal transmission are suggested. Therefore, many compounds that increase acetylcholine activity in Alzheimer's disease patients are being used. Currently, the most effective approach is to inhibit the activity of acetylcholinesterase, which rapidly breaks down acetylcholine at the synapse and blocks nerve signal transduction. In fact, these inhibitors (eg tacrine, donepezil and rivastigmine) are currently marketed as FDA-approved Alzheimer's treatment drugs. In many cases, these drugs are effective in preventing the destructive progression of the disease, but are not well applied to the recovery of the nervous system to the state before the disease.

Although development of a treatment method for reducing the effect of Alzheimer's disease is progressing a lot, it is currently providing temporary symptomatic improvement. In conclusion, the current Alzheimer's disease treatment focuses on improving the symptoms of the disease, not reversing the course of the disease. We know more about the biological knowledge of the disease, but the results of its clinical application have not yet been successful.

On the other hand, stress is emerging as an important health problem for modern society, and more than one-third of adults over the age of 20 in Korea are usually under a lot of stress, and in the case of teenagers, women are more than men, and the older they are. I am feeling a lot of stress. The intensity of stress varies depending on the individual's personality, hobbies, remedies, surrounding environment, and control ability, but most of them accompany depression. Depression is a mental illness caused by stress, and it has extreme consequences such as suicide, and is recognized as a very important disease due to a high recurrence rate and a rapid incidence of patients. The cause of depression is found to be a disorder of neurotransmitters such as adrenaline, dopamine, or serotonin, and it also accompanies brain damage such as atrophy of the hippocampus and inhibition of adult neuron production. Tricyclic antidepressant (TCA) is a representative antidepressant currently known, but it has a disadvantage of having large side effects. In particular, amitriptyline and the like are widely prescribed in Korea, but have many problems such as various side effects.

In addition, nervous system disturbances due to stress are continuously induced, and the current treatment method does not have any special measures to prevent recurrence after prescription of depression drugs, so the content of the administered drugs is lowered to the level of continuous administration. Therefore, it is important to develop a material that has an excellent effect on the correction of neuronal cell apoptosis or neurotransmitter system due to stress. In addition, there are many tendencies to avoid visiting treatment institutions for the treatment of stress-induced depression, or to overlook things such as serotonin nervous system disturbance and brain damage caused by stress, so functional foods that actually have the function of treating stress-related depression. The need for is very great.

US 6245757 B1 US 6380193 B1 US 6288041 B1 US 5580866 B US 5532219 B US 5506097 B US 6136861 B US 6020127 B US 6288089 B1

It is an object of the present invention to provide a substance effective in improving cognitive function, including silk peptides produced by decomposition of silk proteins and natural extracts obtained from natural products as active ingredients.

Another object of the present invention is to provide a pharmaceutical composition for improving cognitive function using the silk peptide and natural extract as active ingredients.

Another object of the present invention is to provide a functional food composition for improving cognitive function by using the silk peptide and natural extract as active ingredients.

In order to achieve the above object, a composition for improving cognitive function comprising a silk peptide and a natural extract according to an embodiment of the present invention comprises a silk peptide produced by decomposition of a silk protein, and 100 parts by weight of the silk peptide It contains 0.1 to 100 parts by weight of a natural extract, and the natural extract is from the group consisting of dandelion extract, Japanese herbaceous herb extract, cystweed extract, hydrangea extract, yulpi extract, plantain extract, gomchwi extract, oyster extract, gondalbi extract, and mixtures thereof Can be chosen.

The silk protein is silk sericin or silk fibro.

The natural extract is a natural product selected from the group consisting of dandelion, single leaf herb, cystaceae, hydrangea, Yulpi, plantain, gomchwi, and mixtures thereof, extracted with a solvent selected from the group consisting of water, alcohols having 1 to 10 carbon atoms, and a mixed solvent thereof Can be.

The cognitive function is related to learning ability, memory ability or concentration.

The composition for improving cognitive function may improve the deterioration of brain or cognitive function accompanying cranial nerve disease.

It relates to a pharmaceutical composition comprising the composition for improving cognitive function.

It relates to a functional food composition comprising the composition for improving cognitive function.

Hereinafter, the present invention will be described in more detail.

In the present invention, the silk peptide is derived from silk, and "silk" refers to a fiber made by sediment of silkworm insects, and preferably means a gajamsa which is sedimented by a silkworm (Bombyx Mori).

In the present invention, "natural extract" means an active ingredient isolated from natural products.

In the present specification, the "nerve cell" includes a central nervous system, a brain, a brain stem, a spinal cord, a neuron constituting a structure such as a junction between the central nervous system and the peripheral nervous system, a nerve support cell, a glia, a Schumann cell, and the like.

In the present specification, "protection of nerve cells" refers to an action of reducing or enhancing neuronal insults, or an action of protecting or restoring nerve cells damaged by neuronal insults.

As used herein, "neural insult" refers to damage to nerve cells or nerve tissue caused by various causes (eg, metabolic causes, toxic causes, neurotoxic causes and chemical causes, etc.).

In the present specification, neurological diseases refer to all diseases caused by damage to the above-described nerve cells or nerve tissues, and in particular, neurological diseases in the brain refer to all diseases caused by damage to nerve cells or nervous tissues of the brain.

In the present specification, "prevention" refers to suppressing the occurrence of a disease or disease in an animal that has not been diagnosed as having a disease or disease, but is prone to such a disease or disease.

As used herein, "treatment" refers to (a) inhibition of the development of a disease or disease; (b) alleviation of the disease or disease; And (c) means the elimination of a disease or disorder.

A composition for improving cognitive function comprising a silk peptide and a natural extract according to an embodiment of the present invention comprises a silk peptide produced by decomposition of silk protein, and 10 to 100 parts by weight of a natural extract based on 100 parts by weight of the silk peptide It includes a part, and the natural extract may be selected from the group consisting of a dandelion extract, a plantain extract, a cypress extract, a hydrangea extract, a yulpi extract, a plantain extract, a gomchwi extract, and a mixture thereof.

Specifically, the silk protein is silk sericin or silk fibroin. Silk protein consists of fibroin and sericin, and fibroin and sericin are present in an average of 75% and 25%, respectively. Fibroin protein has a very high content of glycine and alanine, whereas sericin has an amino acid composition completely different from that of fibroin, and serine accounts for more than 1/3 of the total amino acids. According to a recent study, silk fibroin has a structure in which the H-chain (350 kDa) and the L-chain (26 kDa) are SS bonded, and the glycoprotein P25 (30 kDa) is connected to the two chains through a non-covalent bond. It was identified as a macroprotein of 2.3 BG101a, each of which has a molar configuration of 6:6:1, and due to this structure, the crystalline region and the amorphous region have a block-like polymer property in which the crystalline region and the amorphous region are arranged in a continuous exchange. More specifically, the silk protein is silk fibroin, but is not limited to the above example.

According to an embodiment of the present invention, the degradation of silk protein is through (a) degradation in a calcium salt solution, (b) acid hydrolysis, (c) hydrolysis by enzymes, or (d) a combination of the above methods. It may be implemented, but is not limited thereto. The weight average molecular weight of the silk peptide produced by decomposition by the above method represents a value of about 200-100,000.

In the above (a) calcium salt solution, calcium chloride is generally used, and CaCl ₂ ·ethanol is used. By such decomposition in a calcium salt solution, silk fibroin is decomposed into relatively high molecular weight peptides having a molecular weight of 25,000 to 50,000. Such polymeric peptides are suitable as cosmetic ingredients because of their large molecular weight, but are not suitable as foods and drugs because of their low absorption rate in vivo.

The (b) acid hydrolysis is usually carried out using an inorganic acid (eg, hydrochloric acid), a strong acid is usually used, and the weight average molecular weight of the resulting peptide is about 200 to 10,000. Such a decomposition method has the advantage of forming a peptide having a small molecular weight, but has a problem that it is difficult to obtain a peptide having an appropriate molecular weight. According to an embodiment of the present invention, the weight average molecular weight of the silk peptide obtained by acid hydrolysis is 200 to 3,000, more specifically 300 to 1,500. The peptides of the present invention obtained by acid hydrolysis show a solubility of substantially 100% in water and very low solubility in organic solvents (eg ethanol, methanol, acetone and dimethylformamide).

The hydrolysis by the enzyme (c) is carried out using a proteolytic enzyme. The weight average molecular weight of the finally obtained silk peptide is 200 to 15,000, more specifically 200 to 4,000, even more specifically 300 to 2,000, preferably in the range of 300 to 1,500, which can degrade silk protein. It is carried out using an enzyme or a combination of enzymes.

The degrading enzyme catalyzes hydrolysis by acting specifically or non-specifically on the amino acid sequence. The degrading enzymes are trypsin, pepsin, alcalase, thermoase, flavozyme, sumizyme, protamex, and protein. ) Is selected from the group consisting of, and is not limited to the above example.

In the case of decomposition by the above (d) combination, firstly decomposition with calcium salts or hydrolysis with weak acids or alkalis, and then hydrolyze with enzymes secondarily. More preferably, a silk peptide is obtained by first decomposing with a calcium salt and secondly decomposing with a decomposing enzyme selected from the group consisting of thermose, flavozyme, sumizyme, or a combination thereof. The weight average molecular weight of the silk peptide obtained by such a combinatorial method is 200 to 15,000, specifically 200 to 4,000, more specifically 300 to 2,000, and most specifically 400 to 1,200. By such a method, the silk peptide of the present invention exhibits a solubility of substantially 100% in water and very low solubility in organic solvents (eg, ethanol, methanol, acetone and dimethylformamide).

Silk peptides in the present invention include (a) silk peptides obtained through acid hydrolysis using silk fibroin as a substrate; And (b) primarily decomposing calcium salts using silk fibroin as a substrate, and using trypsin, pepsin, alcalase, thermose, flavozyme, sumyzyme, or a combination thereof. It is a peptide obtained by digestion. More preferred peptides are (a) silk peptides obtained through hydrolysis by adding 20 to 30% aqueous hydrochloric acid solution using silk fibroin as a substrate, or (b) primarily decomposing calcium salts using silk fibroin as a substrate. It is a silk peptide obtained by digestion with flavozyme and sumizyme. At this time, flavozyme and sumizyme were mixed and used in a weight ratio of 1:1.

The composition of the present invention comprising such a silk peptide exhibits efficacy in the prevention or treatment of neurological diseases. Such an action of the present invention generally appears through the protective action of nerve cells.

According to an embodiment of the present invention, the enzyme used to obtain the silk peptide of the present invention is an enzyme that non-specifically degrades an amino acid sequence, and more specifically, consisting of a thermose, flavozyme, sumizyme, and combinations thereof. It is selected from the group, and more specifically flavozyme, sumyzyme, and mixtures thereof, but is not limited to the above examples.

On the other hand, when a natural extract is mixed with the silk peptide in order to exhibit a synergistic effect on improving cognitive function through interaction while maintaining the content of the silk peptide, a certain kind of natural extract is increased by interaction within a certain range. It was confirmed that it can produce an effect. Therefore, it can be seen that when the following natural extracts are used in combination, a more excellent effect can be achieved in improving cognitive function with the same content compared to the case of using silk peptide alone.

The composition for improving cognitive function includes 0.1 to 100 parts by weight of natural extract based on 100 parts by weight of the silk peptide, and preferably 3 to 5 parts by weight of natural extract based on 100 parts by weight of the silk peptide, but in the above example Not limited.

A mixture of silk peptides and natural extracts can significantly increase the effect of improving cognitive function compared to the case of using only silk peptides as an interaction. When containing less than 3 parts by weight of natural extract based on 100 parts by weight of silk peptide, the effect of enhancing cognitive function by mixing natural mixture with silk peptide is insufficient, and when containing more than 5 parts by weight of natural extract, natural As the extract is excessively included, a problem of inhibiting the cognitive function improvement effect of the silk peptide and the natural extract occurs.

The natural extract is selected from the group consisting of dandelion extract, monoleaf extract, cysticweed extract, hydrangea extract, yulpi extract, plantain extract, gomchwi extract, oyster, gondalbi, and mixtures thereof, preferably dandelion extract, monoleaf extract, cystweed It is a mixture of the extract, the extract, the gondalbi extract, and the cornflower extract, but is not limited to the above examples. Compared to the case of mixing dandelion extract, monoleaf extract, cystocarp extract, and cornflower extract with silk peptides, respectively, when the four extracts are mixed, the effect of improving cognitive function can be greatly enhanced through interaction, even if a smaller amount is used. , The effect of improving cognitive function is excellent.

The natural extract is a natural product selected from the group consisting of dandelion, single leaf herb, cystaceae, hydrangea, Yulpi, plantain, gomchwi, and mixtures thereof, extracted with a solvent selected from the group consisting of water, alcohols having 1 to 6 carbon atoms, and a mixed solvent thereof can do.

Dandelion (Taraxacum platycarpum Dahlst) is a perennial herb commonly grown in the mountains and fields of Korea. The growing environment grows in semi-shade or sunny places regardless of the soil fertility. The flower is yellow, 3~7㎝ in diameter, and hangs on the stalk of the same length as the leaf. The fruit is a black seed with silver hairs attached. The difference from the Western Dandelion can be seen in the calyx. In Korea, the native dandelion has the calyx intact, but the Western Dandelion (Taraxacum officinale Weber) is down. This is the easiest way to tell. Young leaves are used for food, and outposts including roots are used for medicinal purposes.

One leaf plant (Lepisorus thunbergianus (Kaulf.) Ching) is an evergreen perennial plant that reproduces with rhizomes or spores. It is distributed in Jeju Island and southern regions and grows attached to the surface of moist rocks or trunks of old trees. The rhizome is about 2 to 3mm in diameter and has narrow lanceolate scales on the outside. The leaves come out from the short root diameter between the nodes, so they seem to come together, linearly, about 10 to 20 ts long, and the tip is sharp. The sporangia group is round and runs in one row on both sides of the main vein of the upper part of the back and turns yellow. There is no curtain. The rhizome is thick, the diameter is about 2 to 3 mm, and the leaves are 10 to 30 ts in length and 5 to 15 mm in width, which is different from the'Aggi single leaf herb'. It is also used for ornamental, bonsai, and medicinal purposes.

Cygnus is a deciduous broad-leaved semi-shrub, and grows sideways by striking a lot of branches, and the small branches have coat hairs and are thin. The height is about 2m. Leaves are 5 to 11 small leaves, oval obovate, oval or long oval, petiole is 1 to 3 cm, odd pinnate compound leaves. The edge is flat and the tip of the leaf is dull or concave, and the bottom of the leaf is round. The root area is used for medicinal purposes.

Hydrangea serrata is a plant of the genus Hydrangea, and the genus Hydrangea belongs to the Hydrangea family, and consists of about 23 kinds of woody shrubs. It is native to the Western Hemisphere and Eastern Asia. Hydrangea plants grown in Korea include H. serrata and dung hydrangea. Hydrangea and wild hydrangea grow in the mountains or fields, and the kinds that are planted in the garden are hydrangea and its varieties. Wild hydrangea can be found all over Korea, but wild hydrangea grows only in Ulleungdo and Jeju Island. In addition, tree hydrangea and American hydrangea are imported from abroad and planted in gardens for landscaping.

Hydrangea serrata, Hydrangea Serrata for.acuminata (Siebold & Zucc) Wilson), Hydrangea serrata for Buezeri Nakai (S. et z.) Hydrangea serrata for.buergeri Nakai.), Hydrangea serrata for Koreana T. Lee (Hydrangea serrata for. coreana T. Lee) and Hydrangea serrata for. fertilis Nakai.

Chestnut (Castanea crenata Sieb) is a deciduous broad-leaved arboreous tree belonging to the oak family, and its fruit, Castane crenata, is composed of fruit, inner skin and outer skin. In order to use chestnut kernels for edible use, since the endothelium, also called Yulpi, has an astringent taste, it is generally used after removal, but Yulpi extract is used for medicinal purposes.

Clematis mandshurica Ruprecht is a deciduous vine plant that grows in the mountains and fields of Korea. The growing environment is grown in sunny or semi-shaded soil fertility. The height is 2~4m, the leaves are opposite, the small leaves are egg-shaped, the ends are gradually narrowed, and the bottom is round or wedge-shaped. The petiole is bent and is like a tendril, and there are no hairs on both sides and the ends are flat. Flowers are white, about 1.2~2㎝ long, and bloom at the end of the main stem and the axils of leaves. The fruit ripens around September. It is used for ornamental purposes, young leaves are used for food, and roots are used for medicinal purposes.

The gondalbi (Ligularia stenocephala) grows in deep mountain wetlands. It is 60-100cm in height. There is no hair on the whole grass, and the rootstock is thick. The leaves on the root remain until the flowers bloom, and the length is 24cm and the butterfly is about 20cm. There are hairs along the veins on the back of the leaf, and there are sharp saw teeth on the edge. The petiole is 40cm long, has no wings, and the bottom is wide. There are 3 leaves on the stem, and the lower one is almost the same as the leaf on the root, but the petiole becomes shorter as it goes upward, making the leaf sheath and the leaf smaller. The flowers are yellow and hang in a racemic order at the end of the stem from August to September. It blooms from bottom to top and is about 3cm in diameter. Bracts are lanceolate, 2~3mm long, and peduncles 1~3.5cm long. The gun is in the shape of a narrow barrel, and there are 5 gun pieces. The corolla is 20-25mm long and 3-4mm wide. The crown hair is shorter than the corolla and is light brown. The fruit is an achene and ripens in October, and is a lanceolate upside down. The color is brownish white, and the length is 6-7mm.

Plantenolinic acid [plantenolic acid], adenine [adenin], folin [pholin], etc. are contained, and it is more effective than ginseng or antler and has anticancer effect. Since plantain leaves have a diuretic substance, drunk plantains dried in sunlight for habitual constipation. You can eat raw leaves with green juice, or you can crush them and pour hot water and drink instead of tea. Outposts or seeds have ingredients that remove phlegm, so when bronchial asthma or phlegm does not stop, drink 15-20g a day and drink between meals. Reduce salt absorption even when swelling occurs due to nephritis, and drink 5-15g of seeds a day. It is good for palliative, diuretic, expectorant, antibacterial, anti-inflammatory, anti-cancer, jaundice, tonsils, hemostasis, and boils.

Gomchwi (Ligularia fischeri) is a perennial plant attached to the Asteraceae family. It flies in deep mountains. The height is about 1m, the root leaf has a long leaf tip, heart-shaped, sharp fine serrations, the stem leaf is small, and the lower part wraps the stem in a sheath shape. From July to September, yellow flowers bloom in a racemic inflorescence.

Specifically, the step of pulverizing a natural product selected from the group consisting of dandelion, single leaf weed, cystic hydrangea, hydrangea, yulpi, plantain, gomchwi, and mixtures thereof; Leaching the pulverized product using an organic solvent; Drying the sample after leaching; Re-leaching the dried sample using an organic solvent; Drying the sample after leaching; Leaching with water; And including the step of leaching, it is possible to obtain a natural extract.

It may further include the step of performing fractionation using an organic solvent the natural extract extracted using the organic solvent.

The method of preparing the extract may be a conventional extraction method in the art, such as an ultrasonic extraction method, a leaching method, and a reflux extraction method. Specifically, it may be an extract obtained by extracting a natural product from which foreign matter is removed by washing and drying with water, alcohol having 1 to 6 carbon atoms, or a mixed solvent thereof, or an extract extracted by sequentially applying the solvents to a sample.

The reflux extraction method is based on 100 mL of an alcohol having 1 to 6 carbon atoms, based on a pulverized product of 10 to 30 g of a natural product, a reflux time of 1 to 3 hours, and an alcohol having 1 to 6 carbon atoms of 50 to 100%. More specifically, based on 100 mL of an alcohol having 1 to 6 carbon atoms, 10 to 20 g of a pulverized product of a natural product, a reflux time of 1 to 2 hours, and 70 to 90% of an alcohol having 1 to 4 carbon atoms are used.

The leaching method is by using an alcohol having 1 to 6 carbon atoms of 15 to 30°C for 24 to 72 hours and 50 to 100%. More specifically, 20 to 25° C., for 30 to 54 hours, and 70 to 80% of alcohol having 1 to 6 carbon atoms.

The ultrasonic extraction method is by 30 to 50 ℃, for 0.5 to 2.5 hours and 50 to 100% of the alcohol having 1 to 6 carbon atoms. Specifically, 40 to 50° C., for 1 to 2.5 hours, and 70 to 80% of alcohol having 1 to 6 carbon atoms.

The extraction solvent may be 2 to 50 times the weight of the sample, and more specifically 2 to 20 times. For extraction, the sample may be left for 1 to 72 hours for leaching in the extraction solvent, and more specifically, for 24 to 48 hours.

After extraction, the extract can be fractionated by sequentially applying a new fractionation solvent. The fractionation solvent used for fractionation is at least one selected from the group consisting of water, hexane, butanol, ethyl acetic acid, ethyl acetate, methylene chloride, and mixtures thereof, and preferably ethyl acetate or methylene chloride.

After obtaining the extract or fraction, a method such as concentration or lyophilization may be additionally used.

Specific examples of diseases to which the composition of the present invention can be applied include, but are not limited to, neurodegenerative diseases, diseases caused by ischemia or reperfusion, and mental diseases. More specifically, neurodegenerative diseases such as dementia, Alzheimer's disease, Huntington's disease, Parkinson's disease and proximal axial sclerosis; Ischemic stroke, such as ischemic stroke or diseases caused by damage to nerve cells following reperfusion; And (c) it can be used for the prevention or treatment of mental disorders such as schizophrenia, depression, and post-traumatic stress disorder.

According to an embodiment of the present invention, a composition comprising a silk peptide and a natural extract is particularly useful for preventing or treating diseases (eg, stroke) caused by damage to nerve cells caused by ischemia or reperfusion.

The above-described efficacy is generally exhibited through the neuroprotective action of a composition comprising a silk peptide and a natural extract. The protective action of nerve cells by the composition comprising the silk peptide and natural extract described above can be exerted through various mechanisms, for example, it is exerted by inhibiting the death of nerve cells, and the death of these nerve cells Includes necrosis and apotosis. In the case of inhibiting apoptosis of nerve cells, one of the targets of the composition comprising the silk peptide of the present invention and the natural extract is caspase (caspase, Guy et.al., Cell 91:443-446(1987)), the above. By inhibiting the activity of the enzyme, apoptosis is suppressed.

The composition comprising the above silk peptide and natural extract exhibits very excellent efficacy in enhancing cognitive function. The composition comprising the silk peptide and natural extract of the present invention is a variety of indicators that support the enhancement of cognitive function, such as memory index (MQ), learning slope, memory maintenance, retrieval efficiency, drawing/memory consistency, language/visual consistency. , Intelligence/memory consistency, and both short-term memory and attentional concentration have excellent efficacy, and as a whole, it acts to greatly enhance human cognitive function.

In addition, a composition comprising a silk peptide and a natural extract according to an embodiment of the present invention exhibits excellent efficacy in improving or preventing deterioration of cognitive function accompanying the above neurological diseases.

In particular, a composition comprising a silk peptide and a natural extract achieves enhancement of cognitive function by inhibiting a decrease in the amount of acetylcholine in the brain.

In addition, the composition comprising the silk peptide and the natural extract inhibits the death of nerve cells caused by stroke to prevent impairment of cognitive function.

According to an embodiment of the present invention, the improvement of cognitive function exerted from the composition comprising the silk peptide of the present invention and the natural extract is enhancement of learning ability and/or memory ability.

By increasing the concentration of acetylcholine, it is known to have an excellent effect in the treatment and prevention of dementia by improving cognitive ability and preventing the progression of dementia, and choline agonists or choline esterase inhibitors are being used for patients. Drugs developed to date include lecithin as an acetylcholine precursor, RS-86 as a receptor agonist, and nicotine, and have been approved by the FDA as an acetylcholinesterase inhibitor. There are tacrine and Aricept, which have been recently approved in Korea, but the effects are temporary, weak, and severe toxicity, so there is still a lot of controversy about their use. However, the composition comprising the silk peptide and the natural extract of the present invention is very useful as a medicine or functional food for enhancing cognitive function because its toxicity to the human body is extremely weak.

Pharmaceutically acceptable carriers included in the pharmaceutical composition of the present invention are commonly used in formulation, and carbohydrate compounds (e.g., lactose, amylose, dextrose, sucrose, sorbitol, mannitol, starch, cellulose, etc.) ), gum acacia, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, salt solution, alcohol, gum arabic, polyethylene glycol, methyl cellulose, methylhydroxy Benzoate, propylhydroxy benzoate, talc, magnesium stearate, mineral oil, and the like, but are not limited thereto. The pharmaceutical composition of the present invention further includes, but is not limited to, a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, and the like in addition to the above components.

The pharmaceutical composition of the present invention may be administered orally or parenterally, and in the case of parenteral administration, it may be administered by intravenous injection, subcutaneous injection, intramuscular injection, or the like.

A suitable dosage of the pharmaceutical composition of the present invention varies depending on factors such as formulation method, mode of administration, age, weight, sex, pathological condition, food, administration time, route of administration, excretion rate and response sensitivity of the patient, Usually, the skilled practitioner can readily determine and prescribe the dosage effective for the desired treatment or prophylaxis. According to a preferred embodiment of the present invention, a suitable dosage is 50 mg-10 g once a day on an adult basis.

The pharmaceutical composition of the present invention is prepared in unit dosage form by formulating using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily carried out by a person having ordinary knowledge in the art. Or it can be prepared by placing it in a multi-dose container. At this time, the formulation may be in the form of a solution, suspension, or emulsion in an oil or aqueous medium, or may be in the form of an extract, powder, granule, tablet or capsule, and may additionally include a dispersant or a stabilizer.

On the other hand, the functional food composition of the present invention includes ingredients commonly added during food production, and includes, for example, proteins, carbohydrates, fats, nutrients, and seasonings. For example, when prepared as a drink, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, cephalic extract, jujube extract, licorice extract, and the like may be additionally included in addition to the silk peptide and natural extracts of the present invention. Considering easy access to food, the food of the present invention is very useful for treating or preventing neurological diseases, treating or preventing diseases caused by oxidative stress, and improving cognitive function.

The composition of the present invention not only exhibits various effects as described above, but also contains natural silk peptides and natural extracts as active ingredients, so that side effects to the human body are extremely less than those of chemically synthesized drugs.

According to the composition for improving cognitive function comprising a silk peptide and a natural extract of the present invention, a composition effective in improving cognitive function can be provided by using an extract derived from a natural product.

The composition for improving cognitive function including the silk peptide and the natural extract of the present invention is provided as a pharmaceutical composition, and compared to the case of using only the conventional silk peptide, a composition with improved cognitive function improvement can be provided.

In addition, in the case of the functional food composition of the present invention, it can be provided as a functional food composition having a high preference while improving cognitive function.

1 is a graph showing the effect of the mixture of the silk peptide and natural extract of the present invention on the cerebral infarction site caused by ischemia.
Figure 2 relates to a graph showing the effect of the mixture of the silk peptide and natural extract of the present invention on the cerebral infarction site caused by ischemia.
Figure 3 relates to a graph showing the antidepressant effect in the case of acute treatment once a mixture of the silk peptide and natural extract of the present invention.
4 is a graph showing the antidepressant effect when the mixture of the silk peptide and natural extract of the present invention is repeatedly treated for a long time.
5 is an experimental result confirming the evaluation of cognitive memory when the mixture of the silk peptide and natural extract of the present invention is treated.
6 is an experimental result confirming the cognitive memory evaluation when the mixture of the silk peptide and natural extract of the present invention was treated.

Hereinafter, embodiments of the present invention will be described in detail so that those skilled in the art can easily implement the present invention. However, the present invention may be implemented in various different forms and is not limited to the embodiments described herein.

[Production Example 1: Preparation of functional silk peptide]

Purification of pure silk fibroin

Silk protein was used by refining a cocoon obtained by rearing Bombyx mori as a messenger upper leaf. First, to remove sericin, the pupa remaining in the cocoon was removed, and 150 g of silkworm cocoon was added to a solution of 8 L of water, 0.45 g of sodium carbonate and 0.75 g of Marcel's soap, followed by boiling treatment twice for 40 minutes each. Thereafter, boiling treatment is performed twice with an appropriate amount of water for about 20 minutes, and then washed with water for about 3 times and dried to dissolve water-soluble sericin. The weight reduction at this time was 37 g (about 25% reduction). After washing with water, it was naturally dried to obtain pure fibroin protein.

Preparation of silk peptide

Based on 35 g of fibroin obtained by the above method, calcium chloride (CaCl ₂ , primary, Mw=110.99)·H ₂ O·ethanol (1:8:2 molar content) was added and reacted at 90° C. for 5 hours. After dissolving, foreign substances were thoroughly filtered with gauze and nonwoven fabric, and then diluted twice with distilled water. Neutral salts were removed with a gel filtration device using a GradiFac system (Pharmacia Biotech, Sephadex G-25 Media, HiLoad P-50 Pump UV-1 Monitor, Sweden) having a diameter of 10 cm and a length of 1 m. Then, to the obtained fibroin solution, 1% of a proteolytic enzyme in which flavozyme and sumyzyme were mixed (1:1) was added, and hydrolysis was performed at 55°C for 5 hours. Then, heat treatment was performed at 100° C. for 5-10 minutes to remove the enzyme activity, and freeze-dried to prepare a powder.

[Production Example 2: Preparation of natural extract]

(1) Preparation of dandelion extract

1) Sample extraction

The dried dandelion tops and roots were leached at room temperature for 48 hours using 70% ethanol, respectively, and the samples were filtered and concentrated.

2) acquisition of fractions

After dissolving 1 g of the above-ground dandelion and roots extracted with 70% ethanol in 30 ml of distilled water, fractionation was performed three times using hexane, and the separated water layer was fractionated again three times. In the third fractionation step, the dandelion upper part extract was fractionated using methyl chloride, and the dandelion root extract was fractionated using a solvent mixed in a weight ratio of Hex: EA = 1:3. After fractionation three times, the separated water layer was again fractionated three times using ethyl acetate, and the separated water layer was again fractionated three times using n-butanol, and the obtained solution was concentrated to obtain each fraction.

(2) Preparation of monoleaflet extract

1) Sample extraction

After leaching the dried plantain for 48 hours at room temperature using 70% ethanol, the sample was filtered and concentrated.

2) acquisition of fractions

After dissolving 1 g of a leaf herb extracted with 70% ethanol in 30 ml of distilled water, fractionation was performed three times using hexane, and the separated water layer was fractionated again three times. In the third fractionation step, the extract of the Japanese leaf herb was fractionated using a solvent mixed in a weight ratio of Hex: EA = 1:3. After fractionation three times, the separated water layer was again fractionated three times using ethyl acetate, and the separated water layer was again fractionated three times using n-butanol, and the obtained solution was concentrated to obtain each fraction.

(3) Preparation of cystocarp extract

1) Sample extraction

The dried cystocarps were leached at room temperature for 48 hours each using 70% ethanol, and the samples were filtered and concentrated.

2) acquisition of fractions

After dissolving 1 g of cystocarps extracted with 70% ethanol in 30 ml of distilled water, fractionation was performed three times using hexane, and the separated water layer was fractionated again three times. In the third fractionation step, the cystocarp extract was fractionated using a solvent mixed in a weight ratio of Hex: EA = 1:3. After fractionation three times, the separated water layer was again fractionated three times using ethyl acetate, and the separated water layer was again fractionated three times using n-butanol, and the obtained solution was concentrated to obtain each fraction.

(4) Preparation of hydrangea extract

1) Sample extraction

Dried hydrangea leaves, fruits and bark were leached at room temperature for 48 hours each using 70% ethanol, and then the sample was filtered and concentrated.

2) acquisition of fractions

After dissolving 1 g of the leaves, fruits and bark of hydrangea extracted with 70% ethanol in 30 ml of distilled water, fractionation was performed three times using hexane, and the separated water layer was fractionated again three times. In the third fractionation step, the hydrangea extract was fractionated using a solvent mixed in a weight ratio of Hex: EA = 1:3. After fractionation three times, the separated water layer was again fractionated three times using ethyl acetate, and the separated water layer was again fractionated three times using n-butanol, and the obtained solution was concentrated to obtain each fraction.

(5) Preparation of Auri extract and Gondalbi extract

After sorting and pulverizing the eel, the pulverized eel and the solvent are mixed in a weight ratio of 1:7 to 1:10, and extracted repeatedly 2 to 8 times for 2 to 12 hours at an extraction temperature of 50 to 100°C. The obtained extract was filtered through a filter cloth, concentrated in vacuo, mixed with the extract and dextrin, and spray-dried to prepare an extract (E6).

In addition, gondalbi extract (E7) was prepared in the same manner.

[Production Example 3: Preparation of a composition for improving cognitive function including silk peptide and natural extract]

According to the composition shown in Table 1 below, a composition for improving cognitive function of S1 to S4, T 1 to T 8 and B 1 to B7 was prepared by mixing the constituents.

Experiment number BG101 E1 E2 E3 E4 E5 E6 E7 S 1 100 One - - - - - - S 2 100 3 - - - - - - S 3 100 5 - - - - - - S 4 100 10 - - - - - - T 1 100 - - - - - One - T 2 100 - - - - - 3 - T 3 100 - - - - - 5 - T 4 100 - - - - - 7 - T 5 100 - - - - - - One T 6 100 - - - - - - 3 T 7 100 - - - - - - 5 T 8 100 - - - - - - 7 B 1 100 - - - - - - - B 2 100 0.5 - - - - - - B 3 100 20 - - - - - - B 4 100 - 3 - - - - - B 5 100 - - 3 - - - - B 6 100 - - - 3 - - - B 7 100 - - - - 3 - -

(Unit weight part)-BG101: silk peptide

-E1: A mixture of dandelion extract, monoleaf extract, cystoid extract, and cornflower extract (weight ratio 1:1:1:1)

-E2: Dandelion extract

-E3: Japanese herb extract

-E4: cystoid extract

-E5: Cornus extract

-E6: Auri extract

-E7: Gondalbee extract

[Experimental Example 1: Ischemic Animal Model Experiment]

The following experiment was conducted to confirm the effect of the composition comprising the silk peptide and natural extract prepared in Preparation Example on the area of cerebral infarction due to ischemia.

Experimental Example 1-1: Local ischemia induction animal model

A. Preparation of drug treatment and local ischemia induction animal model

A local ischemia-inducing animal model was constructed using a male rat (Sprague-Dawley rat) weighing 200-250 g. Drugs were administered orally once 1 hour before induction of ischemia or 1 hour after induction of ischemia (orally administered group, n=6), and ischemia control group (n= 6) administered B 1 to 7 at the same dose as the drug treatment group. After intramuscular injection of ketamine 30-40 mg/kg into experimental animals, a skin incision was made to the neck in the supine position, and the common carotid artery, external carotid artery, and internal carotid artery were artery) and separated from surrounding tissues. First, the upper upper thyroid artery, the branch of the external carotid artery, the larynx, and the artery are electrically cauterized, the pterygopalatine artery, which is the branch of the internal carotid artery, is electro-cauterized, and the external carotid artery is cut, and a 4-0 nylon thread (ETHICON, INC) is externally cauterized. After insertion into the internal carotid artery through the carotid artery, a nylon thread was placed at the branch of the carotid artery with 16 to 18 mm in it to occlude the origin of the Middle Cerebral Artery.

B. Experiment on the effect of reducing cerebral infarction by ischemia

Six hours after the induction of ischemia, the animals were shortened and the brain was removed. The extracted brain was sectioned at intervals of 2 mm from the anterior pole, and reacted with 2% triphenyl tetrazolium chloride (TTC, Sigma) solution at 37°C for 30 minutes, and then 4% paraformaldehyde ( Sigma) solution and fixed. After taking the stained tissue section, the image was measured using the MCID image processing system (Imaging Research Inc.) to measure the area of the area that turned white due to the occurrence of cerebral infarction unlike the normal area stained in red. The average value was calculated after calculating the ratio of the area of cerebral infarction. In addition, the ratio of the volume occupied by the cerebral infarction site in the total volume of each brain slice was measured.

The silk peptide of the present invention reduces the ischemia-induced cerebral infarction to a significant level with respect to the control group. In the result of comparing each of the brain sections in FIG. 1, it was observed that the effect of reducing cerebral infarction was not concentrated on a specific area and appeared overall (P<0.05). In addition, as a result of measuring the ratio of the volume of the cerebral infarction to the volume of the whole brain section in FIG. 2, the pretreatment of S 1 to 4 and T 1 to 8 showed a significant effect on reducing the cerebral infarction area due to local ischemia. In the accompanying Figures 1 and 2, each measured value represents the mean ± standard error. Therefore, it can be seen that the silk peptide of the present invention can be usefully used in functional foods and drugs related to the prevention and treatment of ischemic stroke.

[Experimental Example 2: Depression Animal Model Experiment]

Experimental Example 2-1: Preparation of experimental animals

Experimental animals are male white papers (Sprague Dawley, 140-180 g, Korea Experimental Animal Center), which are put in 4 per cage for one week in a constant environment (indoor temperature 25±1℃, relative humidity 60±10%). It was used in experiments after adapting to the environment by ingesting water and feed without restriction. Among the white papers, cases in which there was little movement in general breeding condition, poor development status, abnormal homologous behavior in forced swimming, or significantly decreased swimming ability were excluded, and a total of 50 animals were used in this experiment.

Experimental Example 2-2: Depression Animal Model Experiment

In this experiment, a standardized test method called the behavioral despair test, the forced swimming test (FST), was used. Ecologically, white papers hate water, so when exposed to water, they exhibit characteristic behaviors to escape from this environment. In other words, the experimental animal is forced to swim to escape from the water and does not swim anymore after a certain period of time. Using this principle, the forced swimming test method is known as a basic experiment to search for antidepressant effects during drug development. have. The FST process was carried out as follows according to the method of Porsolt et al. (Porsolt et al., Eur. J. Pharmacol. 51(3), 291-294, 1978), which was the first proposer.

First, a transparent acrylic cylindrical water tank having a height of 40 cm and a diameter of 18 cm was filled with water at 25° C. to a height of 15 cm, and the white paper of Experimental Example 2-1 was forcibly removed thereto and then allowed to stand for 15 minutes. For the first few minutes, the white paper showed severe resistance to escape from this, but as time passed, the time to show the immobilization time gradually increased, and the body remained almost immobilized for the last few minutes. A typical immobile state is a state in which a white paper floats on the water with only a part of the face lifted up on the surface, showing only slight movements to maintain the balance of the body. After forced swimming, the white paper was wiped dry, dried for 30 minutes with a dryer at 37℃, and returned to the breeding box.

After the first forced swimming, the second forced swimming was performed 24 hours later. In this experiment, the secondary forced swimming was allowed to stay in the tank for only 5 minutes under the same conditions as the first forced swimming, and the total immobility time during this period was measured. In the secondary forced swimming white paper, most of the results of learned helplessness show the immobile state for more time than in the primary forced swimming. Since the increase in immobility, which is considered a symptom indicator of depression in the forced swimming model, is reduced again by the treatment of antidepressants, this reduction in immobility is thought to be related to the action of antidepressants. In the forced swimming test, some drugs do not show the effect during acute treatment of the drug, but may show effect during long-term treatment, so in this experiment, the drug was treated for 7 days and then a secondary strong swimming was attempted. In general, the antidepressant effect of antidepressants is obtained after at least two weeks of drug administration, so this method is widely used in forced swimming tests. For the measurement of immobilization, video was taken for the entire process of the second forced swimming, and the immobility time was measured to compare and evaluate the immobility time between the control group and the experimental group. Through video screen analysis, three trained evaluators measured the immobility time with a stopwatch to obtain the average value between evaluators and used it as analysis data.

Method of administration

Experiment numbers S 1 to 4, T 1 to 8, and B 1 to 7 of the present invention were prepared as 100 mg/ml solutions and administered orally. All samples were dissolved in distilled water and administered orally. In the case of single administration, it was administered 1 hour before the second forced swimming, and in the case of long-term repeated administration for 7 days, it was administered 30 minutes after the first forced swimming and repeatedly administered for 7 days.

Antidepressant effect in one acute treatment

The antidepressant effect was confirmed during one acute treatment of S 1 to 4, T 1 to 8 and B 1 to 7 of the present invention (1 g/kg). Dosage is 20 mg/kg per dose, referring to the results of previous studies (Eur. J. Pharmacol. 138(3), 413-416, 1987; Neuropharmacology 28(3), 229-233, 1989). I did. The experimental results are shown in FIG. 3.

As can be seen in Figure 3, it can be seen that the average immobility time by acute treatment was significantly shortened in the experimental group administered S 1 to 4 and T 1 to 8 of the present invention compared to the control group (**, P <0.05). In the accompanying Figure 3, each measured value represents the mean ± standard deviation.

Antidepressant effect during long-term repeated treatment (7 days)

The antidepressant effect was confirmed during long-term repeated treatment of S 1 to 4 and T 1 to 8 of the present invention. Examples 1 to 4 were administered orally at 50 mg/kg once a day for 7 days, and the same experiment as in the case of once treatment was conducted. The experimental results are shown in FIG. 4.

As shown in Figure 4, the average immobility time due to long-term treatment was shortened by the administration of B 1 to 7 compared to the control group (P <0.1). However, it can be seen that the immobility time was significantly shortened in the experimental group administered with S 1 to 4 and T 1 to 8 (P <0.05). In the accompanying Figure 4, each measured value represents the mean ± standard deviation.

[Experimental Example 3: Animal model experiment for cognitive function improvement]

Experimental Example 3-1: Preparation of experimental animals

Experimental animals are male white papers (Sprague Dawley, 140-180 g, Korea Experimental Animal Center), which are put in 4 per cage for one week in a constant environment (indoor temperature 25±1℃, relative humidity 60±10%). Water was provided without restriction, and at this time, limited meals were provided to maintain 80% of the body weight. A total of 50 animals were used in this experiment. From 3 days before training, the test was conducted by adapting to the maze for 5 minutes.

Experimental Example 3-2. Delayed alternation test

There are a total of three passages (left, right, center), and each passage entrance was prepared with a T-shaped maze with partitions so that the experimenter could control the entry of animals.

In the first trial, the starting box was acclimated for 1 minute. The first trial was a'forced selection trial', in which one passage was blocked with a partition, and when an animal entered the other passage, the rear was blocked with a partition. The animal was considered to have entered when the animal's limb passed through the passageway entrance. Animals were allowed to feed in the passage for 60 seconds.

From the next trial, the'free choice trial' allowed the animals to freely select the direction of the passageway (left or right) starting from the starting box. Animals were compensated for food only when they entered the passageway opposite to the passageway entered in the previous trial.

The trial interval was configured with a delay of 5 seconds and 20 seconds, and the cut-off time of each trial was 60 seconds. The number of times the animal entered the passageway to be strengthened correctly and the time it took to enter the passage was measured. The same procedure was performed and evaluated for 9 days of 10 trials per day.

Method of administration

Test Nos. B1 and S1 to S4 of the present invention were prepared as a 100 mg/ml solution and administered orally. All samples were dissolved in distilled water and administered orally.

Cognitive memory evaluation result

Results of the T-maze experiment for the group administered with B1, S1 to S4 are shown in FIGS. 5 and 6. 5 shows the experiment was conducted by configuring the trial interval of 5 seconds, and the performance gradually improved during the training period for 9 days. In particular, it was confirmed that the excellent performance enhancing effect in the S2 and S3 administration groups.

6 shows that the experiment was conducted by configuring the trial interval of 20 seconds, and it was confirmed that the performance gradually improved during the training period for 9 days, but it was confirmed that the effect of improving the performance was less than that when the training period was composed of 5 seconds. In particular, the effect was insufficient in B1, S1, and S5, and in the S2 and S3 administration groups, excellent performance improvement effect was confirmed as when the trial interval was composed of 5 seconds.

Although the preferred embodiments of the present invention have been described in detail above, the scope of the present invention is not limited thereto, and various modifications and improvements by those skilled in the art using the basic concept of the present invention defined in the following claims are also present. It belongs to the scope of rights of

Claims (7)

Contains silk peptides produced by the degradation of silk proteins,
Based on 100 parts by weight of the silk peptide,
Contains 0.1 to 100 parts by weight of natural extract,
The natural extract is a mixture of dandelion extract, monoleaf extract, cystocarp extract, and hydrangea extract
A composition for improving cognitive function, including silk peptides and natural extracts. The method of claim 1,
The silk protein is silk sericin or silk fibroin
A composition for improving cognitive function, including silk peptides and natural extracts. The method of claim 1,
The natural extract is extracted with a solvent selected from the group consisting of water, an alcohol having 1 to 10 carbon atoms, and a mixed solvent thereof.
A composition for improving cognitive function, including silk peptides and natural extracts. The method of claim 1,
The cognitive function is learning ability, memory ability or concentration.
A composition for improving cognitive function, including silk peptides and natural extracts. The method of claim 1,
The composition improves the deterioration of brain or cognitive function accompanying cranial nerve disease
A composition for improving cognitive function, including silk peptides and natural extracts. Comprising the composition according to any one of claims 1 to 5
A pharmaceutical composition for improving cognitive function. Comprising the composition according to any one of claims 1 to 5
Functional food composition for improving cognitive function.

Images